Observational studyScientific reports2018
Confirmation of a metastasis-specific microRNA signature in primary colon cancer.
Observational study in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Epigenetic Biomarkers in Colorectal Cancer Patients Receiving Adjuvant or Neoadjuvant Therapy: A Systematic Review of Epidemiological Studies.International journal of molecular sciences · 2019Pooled it
- Article
- Discovery of Novel miRNAs in Colorectal Cancer: Potential Biological Roles and Clinical Utility.Non-coding RNA · 2023Article
- Prognostic modelling of colorectal cancer based on oxidative stress-related genes.Journal of cancer research and clinical oncology · 2023Article
- Dual mechanism of Let-7i in tumor progression.Frontiers in oncology · 2023Review
- The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer.Clinical colorectal cancer · 2022Review
- Molecular Pathology of Lung Cancer.Cold Spring Harbor perspectives in medicine · 2022Review
- The Value of Serum miR-139-3p Expression Level in Predicting Postoperative Survival of Colon Cancer Patients.International journal of general medicine · 2022Article
- Identifying Diagnostic MicroRNAs and Investigating Their Biological Implications in Rectal Cancer.JAMA network open · 2021Article
- Biological Implications and Clinical Potential of Metastasis-Related miRNA in Colorectal Cancer.Molecular therapy. Nucleic acids · 2021Review
- SEMA6B Overexpression Predicts Poor Prognosis and Correlates With the Tumor Immunosuppressive Microenvironment in Colorectal Cancer.Frontiers in molecular biosciences · 2021Article
- Roles and regulatory mechanisms of miR-30b in cancer, cardiovascular disease, and metabolic disorders (Review).Experimental and therapeutic medicine · 2021Review
- let-7e downregulation characterizes early phase colonic adenoma in APCMin/+ mice and human FAP subjects.PloS one · 2021Article
- Comprehensive evaluation of microRNA-10b in digestive system cancers reveals prognostic implication and signaling pathways associated with tumor progression.Journal of Cancer · 2021Article
- Overview of microRNAs as liquid biopsy biomarkers for colorectal cancer sub-type profiling and chemoresistance.Cancer drug resistance (Alhambra, Calif.) · 2021Review
- Defining lung cancer stem cells exosomal payload of miRNAs in clinical perspective.World journal of stem cells · 2020Review
- A Multi-Omics Analysis of Bone Morphogenetic Protein 5 (Biomedicines · 2020Article
- Identification of an Immune-Related Nine-lncRNA Signature Predictive of Overall Survival in Colon Cancer.Frontiers in genetics · 2020Article
- MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside.World journal of gastroenterology · 2018Review
- NUAK1 knockdown suppresses prostate cancer cell epithelial-mesenchymal transition, migration, and invasion through microRNA-30b-5p.International journal of clinical and experimental pathology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 8 institutions in 2 countries.
Funding
Abstract
The identification of patients with high-risk stage II colon cancer who may benefit from adjuvant therapy may allow the clinical approach to be tailored for these patients based on an understanding of tumour biology. MicroRNAs have been proposed as markers of the prognosis or treatment response in colorectal cancer. Recently, a 2-microRNA signature (let-7i and miR-10b) was proposed to identify colorectal cancer patients at risk of developing distant metastasis. We assessed the prognostic value of this signature and additional candidate microRNAs in an independent, clinically well-defined, prospectively collected cohort of primary colon cancer patients including stage I-II colon cancer without and stage III colon cancer with adjuvant treatment. The 2-microRNA signature specifically predicted hepatic recurrence in the stage I-II group, but not the overall ability to develop distant metastasis. The addition of miR-30b to the 2-microRNA signature allowed the prediction of both distant metastasis and hepatic recurrence in patients with stage I-II colon cancer who did not receive adjuvant chemotherapy. Available gene expression data allowed us to associate miR-30b expression with axon guidance and let-7i expression with cell adhesion, migration, and motility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.